Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 6Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Prostatic Neoplasms 6Leukemia, Myeloid, Acute 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Uterine Cervical Neoplasms 3Sarcoma 3Pancreatic Neoplasms 3Multiple Myeloma 3Lung Neoplasms 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Rectal Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Melanoma 2Lymphoma 2Leukemia, Biphenotypic, Acute 2Colonic Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 2Burkitt Lymphoma 2Uterine Cervical Dysplasia 1Tongue Neoplasms 1Thrombocytosis 1Thrombocytopenia 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Pruritus 1

Interventions

Rituximab 4ibrutinib 2fludarabine phosphate 2fludarabine 2blinatumomab 2Vorinostat 2Radiation 2Nivolumab 2Lenalidomide 2Gemcitabine 2Cytarabine 2Cyclophosphamide 2CT-P10 2umbralisib 1ublituximab 1tafasitamab 1polatuzumab vedotin 1pembrolizumab 1ofatumumab 1molibresib 1magrolimab 1iberdomide 1glofitamab 1entinostat 1cirmtuzumab 1carmustine, poliferprosan 20 drug combination 1asparaginase erwinia chrysanthemi recombinant 1X-Rays 1Tacrolimus 1Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, B-Cell × Biopsy × Clear all
NCT05936229 2024-07-12

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Fred Hutchinson Cancer Center

Phase 1/2 Withdrawn
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡